Genolair®
INN: omalizumab
(solution for subcutaneous administration)
Description
Indications for use
Omalizumab is a humanized monoclonal antibody derived from recombinant DNA that selectively binds to immunoglobulin (IgE).
Omalizumab binds to IgE and prevents its interaction with the high-affinity FcεRI receptor. Thus, there is a decrease in the amount of free IgE, which is the trigger for the cascade of allergic reactions.
Omalizumab is the only class of biological anti-IgE therapy recommended for the treatment of atopic bronchial asthma, helps to eliminate or reduce the use of glucocorticosteroids, and also reduces the number and frequency of exacerbations.
- Treatment of moderate to severe persistent atopic asthma, the symptoms of which are inadequately controlled by inhaled glucocorticosteroids in patients aged 6 years and older;
- Treatment of chronic spontaneous (idiopathic) urticaria refractory to H1-histamine receptor antagonists in patients aged 12 years and older;
- Treatment of seasonal and perennial allergic rhinitis when previous therapy is insufficient in patients aged 12 years and older;
- Treatment of nasal polyposis when intranasal glucocorticosteroids are insufficient in patients aged 18 years and older.